预测MRI引导聚焦超声治疗子宫肌瘤后症状持久缓解的因素:一项在8个学术中心开展的多中心试验
这项前瞻性多中心试验纳入99例子宫肌瘤患者,分析MRI引导聚焦超声治疗后症状持久缓解的预测因素。结果显示,消融比(无灌注体积与总肌瘤负荷之比)是唯一独立预测因素,比值低于30%者症状改善较差且缺乏持久反应。
要点
- 消融比(无灌注体积/总肌瘤负荷)是症状持久缓解的唯一独立预测因素(p=0.01)。
- 消融比低于30%者症状严重度评分改善较差,且缺乏持久临床反应。
- 无T2加权Funaki 2型肌瘤、总肌瘤负荷较低、消融比较高与12及24个月持续成功相关。
核心结论
- 无灌注体积相对总肌瘤体积增加与异常子宫出血和肿块相关困扰的症状持久减轻显著相关。
研究设计与样本
- 前瞻性多中心试验,8个学术中心,99例子宫症状性肌瘤患者接受MRgFUS治疗,基线和治疗日行盆腔MRI,使用子宫肌瘤症状-生活质量问卷计算症状严重度评分,随访6、12、24、36个月。
诊断标准与关键数值
- 治疗成功定义为症状严重度评分改善≥30分且持续至12和24个月;单因素分析中预测因素包括消融比(NPV/TFL)增加(p=0.002)、总肌瘤负荷降低(p=0.04)和无T2加权Funaki 2型肌瘤(p=0.02);多因素分析中消融比是唯一预测因素(p=0.01);消融比低于30%者症状严重度评分改善较少且缺乏持久临床反应,与30-79%者相比p=0.03,与≥80%者相比p=0.01。
临床应用与阅片要点
- 患者选择应强调影像学上可能实现高消融比者(如设备可及性、Funaki分型),并考虑总肌瘤负荷而非仅主要症状性肌瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To identify variables predictive of durable clinical success after MRI-guided focused ultrasound (MRgFUS) treatment of uterine fibroids.
MATERIALS AND METHODS: In this prospective, multicenter trial, 99 women with symptomatic uterine fibroids were treated using MRgFUS. Pelvic MRI was obtained at baseline and treatment day. The Uterine Fibroid Symptom-Quality of Life questionnaire was used to calculate a symptom severity score (SSS) at baseline and 6, 12, 24, and 36 months following treatment. Clinical, imaging, and treatment variables were correlated with symptom reduction sustained through the 12- and 24-month time points using univariable and multivariable logistic regression analyses. A novel parameter, the ratio of non-perfused volume to total fibroid load (NPV/TFL), was developed to determine association with durable outcomes.
RESULTS: Post-treatment, mean symptom severity decreased at the 6-, 12-, 24-, and 36-month follow-ups (p < 0.001, all time points). In univariable analysis, three variables predicted treatment success (defined by ≥ 30-point improvement in SSS) sustained at both the 12-month and 24-month time points: increasing ratio of NPV/TFL (p = 0.002), decreasing total fibroid load (p = 0.04), and the absence of T2-weighted Funaki type 2 fibroids (p = 0.02). In multivariable analysis, the NPV/TFL was the sole predictor of durable clinical success (p = 0.01). Patients with ratios below 30% had less improvement in SSS and lacked durable clinical response compared with those between 30-79 (p = 0.03) and ≥ 80% (p = 0.01).
CONCLUSION: Increased non-perfused volume relative to total fibroid volume was significantly associated with durable reduction of symptoms of abnormal uterine bleeding and bulk bother.
CLINICAL RELEVANCE STATEMENT: Patient selection for sustained clinical benefit should emphasize those with likelihood of achieving high ablation ratios, as determined by imaging (e.g., device access, Funaki type) and by considering the total fibroid load, not just the primary symptomatic fibroid.
TRIAL REGISTRATION: Clinical trial ID: NCT01285960.
KEY POINTS: • Patient selection/treatment approach associated with durable symptom relief in MRI-guided focused ultrasound ablation of uterine fibroids remains unclear. • The ablation ratio, non-perfused volume/total fibroid volume, was positively associated with sustained symptom relief in both bleeding and bulk bother at 1- and 2-year follow-ups. • Selecting patients with imaging features that favor a high ratio of ablation to total fibroid load (including non-targeted fibroids) is the main factor in predicting durability of symptom relief after uterine fibroid treatment.
引用
- Bitton RR, Fast A, Vu KN, et al. What predicts durable symptom relief of uterine fibroids treated with MRI-guided focused ultrasound? A multicenter trial in 8 academic centers. Eur Radiol. 2023. PMID: 37553488. doi:10.1007/s00330-023-09984-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。